| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.18 | 0.0008 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.093 | 0.003 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.12 | 0.006 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.007 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.007 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.093 | 0.008 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.083 | 0.009 |